Endocrine & Hormone Panel

Navigation & Literature

• Parent Silo: 03 - Diagnostics & Quantified Self MOC
• Literature Dossier: Endocrine & Hormone Panel - References

---

1. Reference Range Comparison (Standard vs. Longevity Optimal)

Sub-Marker	Standard Clinical Range	Longevity / Functional Optimal	Primary Unit	Physiological Meaning
Total Testosterone (LC/MS-MS)	$264–916\text{ ng/dL}$ (M) / $15–70\text{ ng/dL}$ (F)	$600–900\text{ ng/dL}$ (M) / $35–60\text{ ng/dL}$ (F)	$\text{ng/dL}$	Anabolic, neuroprotective, and metabolic androgen pool
Free Testosterone (Equilibrium Dialysis)	$5.0–21.0\text{ pg/mL}$ (M) / $0.2–2.2\text{ pg/mL}$ (F)	$15.0–25.0\text{ pg/mL}$ ($2.0–2.5\%$ of Total) (M)	$\text{pg/mL}$	Bioavailable unbound fraction active at intracellular androgen receptors
Estradiol ($E_2$, Sensitive LC/MS-MS)	$8–43\text{ pg/mL}$ (M) / Phase-dependent (F)	$20–35\text{ pg/mL}$ (M) / $80–200\text{ pg/mL}$ luteal (F)	$\text{pg/mL}$	Bone mineral density, endothelial eNOS, synaptic plasticity, and libido regulator
SHBG (Sex Hormone Binding Globulin)	$16.5–55.9\text{ nmol/L}$ (M) / $24–122\text{ nmol/L}$ (F)	$25–40\text{ nmol/L}$ (M) / $45–75\text{ nmol/L}$ (F)	$\text{nmol/L}$	Hepatic glycoprotein controlling free sex-steroid bioavailability and insulin status
DHEA-S	$70–495\mu \text{g/dL}$ (age-adjusted)	$250–400\mu \text{g/dL}$ (M) / $180–300\mu \text{g/dL}$ (F)	$\mu \text{g/dL}$	Adrenal zona reticularis neurosteroid reserve and cortisol counter-regulator
IGF-1 (Insulin-Like Growth Factor 1)	$55–240\text{ ng/mL}$	$110–160\text{ ng/mL}$ (U-shaped longevity sweet spot)	$\text{ng/mL}$	Somatotropic GH/mTOR tissue-repair mediator vs. mitogenic aging trade-off
Morning Serum Cortisol (8 AM)	$6.2–19.4\mu \text{g/dL}$	$11.0–16.0\mu \text{g/dL}$	$\mu \text{g/dL}$	HPA-axis glucocorticoid awakening peak and metabolic mobilization signal
LH / FSH	$1.7–8.6\text{ mIU/mL}$ (M)	$3.0–6.5\text{ mIU/mL}$ (M)	$\text{mIU/mL}$	Pituitary gonadotropin drive distinguishing primary (testicular/ovarian) vs. secondary hypogonadism
Prolactin	$4.0–15.2\text{ ng/mL}$ (M) / $4.8–23.3\text{ ng/mL}$ (F)	$5.0–10.0\text{ ng/mL}$ (M) / $6.0–14.0\text{ ng/mL}$ (F)	$\text{ng/mL}$	Lactotroph peptide inversely regulated by tuberoinfundibular dopamine ($D_2$) tone

---

2. Physiological Significance & Hazard Curves

The Anabolic-Metabolic Androgen Axis (Testosterone, SHBG, Estradiol)

Testosterone regulates skeletal muscle satellite cell proliferation, erythropoiesis, bone trabecular density, dopaminergic motivation, and insulin sensitivity. However, standard electrochemiluminescence immunoassays (ECLIA) suffer from cross-reactivity at low concentrations; liquid chromatography–tandem mass spectrometry (LC/MS-MS) for Total Testosterone and Equilibrium Dialysis (or Vermeulen calculation using albumin + SHBG) for Free Testosterone are mandatory.

• SHBG Dynamics: Hepatic SHBG synthesis is suppressed by hyperinsulinemia, visceral fat, and hypothyroidism, and elevated by high thyroid hormone, estrogens, low-protein/caloric restriction, or hepatic cirrhosis. High SHBG ($>55\text{ nmol/L}$ in men) can trap normal Total Testosterone ($700\text{ ng/dL}$), producing functional androgen deficiency with low Free T.
• Estradiol ($E_2$) U-Curve in Men: Both overly suppressed estradiol ($<15\text{ pg/mL}$, often iatrogenic from aromatase inhibitor overuse) and elevated estradiol ($>45\text{ pg/mL}$ from visceral adipose aromatase activity) increase mortality in men with heart failure or cardiometabolic risk. Low $E_2$ causes rapid osteopenia, joint pain, endothelial dysfunction, and loss of libido.

The Somatotropic Longevity Paradox (IGF-1 U-Shaped Hazard Curve)

IGF-1 mediates the anabolic, neuroprotective, and musculoskeletal effects of pulsatile growth hormone (GH). Large prospective biobank analyses (UK Biobank $N>400,000$; Framingham) reveal a pronounced U-shaped relationship between serum IGF-1 and all-cause mortality:

• Too Low ($<90–100\text{ ng/mL}$): Associated with elevated hazards for cardiovascular mortality, sarcopenia, frailty, and neurodegenerative cognitive decline (vascular/neuronal repair deficit).
• Too High ($>180–200\text{ ng/mL}$): Constitutive hyperactivation of the IIS (insulin/IGF-1) and mTORC1 pathways suppresses FOXO3 transcription and autophagy, increasing cancer mortality hazard ratios.
• Longevity Optimal ($110–160\text{ ng/mL}$): Balances somatic tissue preservation, neurogenesis, and vascular elasticity against oncogenic mitogenesis.

HPA Axis & Neurosteroid Reserve (Cortisol : DHEA-S Ratio & Prolactin)

Adrenal DHEA-S peaks at age 20–25 and declines by ~2% per year (“adrenopause”). Chronic psychosocial or physiological stress shifts adrenal pregnenolone/17-OH-pregnenolone steroidogenesis toward cortisol at the expense of DHEA-S, elevating the Cortisol : DHEA-S ratio—a robust predictor of hippocampal atrophy, immunosenescence, and frailty. Elevated prolactin ($>15\text{ ng/mL}$ in men) reflects reduced hypothalamic dopamine tone (tuberoinfundibular pathway), suppressing GnRH pulsatility, LH/Testosterone secretion, and sexual refractory recovery.

---

3. Root Causes of Dysregulation

• Secondary Hypogonadism (Low T + Low/Normal LH): Sleep deprivation or obstructive sleep apnea (majority of daily testosterone pulse occurs during first REM/SWS transitions; see Sleep Architecture), chronic caloric deficit or overtraining syndrome (Recovery & Supercompensation), hyperprolactinemia, and visceral obesity (adipocyte aromatase converting T $\to E_2$, which suppresses hypothalamic kisspeptin/GnRH).
• Primary Hypogonadism (Low T + Elevated LH/FSH): Leydig cell oxidative stress, varicocele/testicular hyperthermia, environmental endocrine disruptors (phthalates, BPA, Atrazine), and micronutrient deficiencies (zinc, magnesium, vitamin D, boron).
• Skewed Cortisol / Low DHEA-S: Circadian disruption, chronic sympathetic overdrive, nighttime blue light exposure, and HPA axis dysregulation (HPA Axis & Cortisol Modulation).

---

4. Actionable Interventions

Foundational Protocols (01 - Foundations)

• Sleep-Dependent Gonadotropin Pulses: Protect 7.5–8.5 hours of uninterrupted sleep; sleeping $5\text{ h/night}$ for 1 week reduces daytime testosterone by 10–15% in young men (see Sleep Architecture and Sleep Environment & Hygiene).
• HPA Axis Recalibration: Anchor morning cortisol awakening response (CAR) with 10,000+ lux outdoor light within 30 minutes of waking per Circadian Entrainment & Zeitgebers and buffer afternoon allostatic load via NSDR & Neuroplasticity and HPA Axis & Cortisol Modulation.
• Heavy Compound Resistance Training: Mechanical loading stimulates androgen receptor density and acute GH/IGF-1 myokine signaling via Resistance Training & Hypertrophy.

Molecular & Pharmacological Interventions (02 - Compounds & Molecules)

• Micronutrient Cofactors: Optimize intracellular zinc ($15–30\text{ mg}$), magnesium ($400\text{ mg}$ via Magnesium Forms & Bioavailability), Vitamin D3 ($4000–5000\text{ IU}$ via Vitamin D3, K2 & Calcium Homeostasis), and Boron ($3–6\text{ mg/day}$ cycled to lower excess SHBG by 10–15%).
• HPG Axis & Adaptogenic Modulators: Ashwagandha (KSM-66/Shoden $300–600\text{ mg}$) and Tongkat Ali (Eurycoma longifolia $200–400\text{ mg}$) or Fadogia agrestis via Adaptogens; Pyridoxal-5’-Phosphate (P5P $50\text{ mg}$) and L-Tyrosine via Dopaminergics & Catecholamines to lower prolactin.
• Somatotropic & Bioregulator Peptides: If IGF-1 is suboptimal ($<100\text{ ng/mL}$), utilize pulsatile GH Secretagogues (Ipamorelin, CJC-1295, Tesamorelin) to preserve physiological feedback loops without supraphysiological IGF-1 spikes; if IGF-1 is chronically excessive, consider intermittent mTOR & Autophagy Modulators (Rapamycin).

---

5. Key Scientific Evidence Summary

• Yeap et al. (2024, Annals of Internal Medicine): Individual participant data meta-analysis ($n=24,109$ men) demonstrating significantly increased all-cause and cardiovascular mortality when baseline Total Testosterone falls below $213–317\text{ ng/dL}$ or Free Testosterone drops below $150–220\text{ pmol/L}$.
• Jankowska et al. (2009, JAMA): Revealed the U-shaped mortality curve for serum estradiol in men, where both lowest ($<12.9\text{ pg/mL}$) and highest ($\ge 37.4\text{ pg/mL}$) quintiles experienced 3–4$\times$ higher mortality than the balanced middle quintile ($21.8–30.1\text{ pg/mL}$).
• Mukama et al. (2023, JCEM): UK Biobank cohort ($n=407,555$) defining the U-shaped hazard curve of IGF-1 with all-cause, cardiovascular, and cancer mortality.

See full bibliographic details and quantitative effect sizes in Endocrine & Hormone Panel - References.